Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: CTXR stock price vs FNKO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FNKO's multiple
Needs FNKO P/S.
Implied fair value · at CTXR's multiple
Needs CTXR P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CTXR FY 2022 (ended Sep 30, 2022) · FNKO FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Citius Pharmaceuticals, Inc. · implied price per share
Bear
$0.09
Base
$0.11
Bull
$0.13
FUNKO, INC. · implied price per share
Bear
-$3.00M
Base
-$3.53M
Bull
-$4.06M
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.01x
0.66x
Net debt / EBITDA
Leverage against operating earnings
0.09x
4.39x
Cash and equivalents
Liquid reserves on the balance sheet
$4.25M
$42.15M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zomedica Corp.
CTXR vs ZOM
Aquestive Therapeutics, Inc.
CTXR vs AQST
ACADIA PHARMACEUTICALS INC
CTXR vs ACAD
AMGEN INC
CTXR vs AMGN
GILEAD SCIENCES, INC.
CTXR vs GILD
AbbVie Inc.
CTXR vs ABBV
JAKKS PACIFIC INC
CTXR vs JAKK
HASBRO, INC.
CTXR vs HAS
MATTEL INC /DE/
CTXR vs MAT
AMAZON COM INC
CTXR vs AMZN
$1.00M
$123.36M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Live quote
